These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8404618)

  • 1. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity.
    Zarjevski N; Cusin I; Vettor R; Rohner-Jeanrenaud F; Jeanrenaud B
    Endocrinology; 1993 Oct; 133(4):1753-8. PubMed ID: 8404618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracerebroventricular administration of neuropeptide Y to normal rats has divergent effects on glucose utilization by adipose tissue and skeletal muscle.
    Zarjevski N; Cusin I; Vettor R; Rohner-Jeanrenaud F; Jeanrenaud B
    Diabetes; 1994 Jun; 43(6):764-9. PubMed ID: 8194661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracerebroventricular administration of neuropeptide Y to normal rats increases obese gene expression in white adipose tissue.
    Sainsbury A; Cusin I; Doyle P; Rohner-Jeanrenaud F; Jeanrenaud B
    Diabetologia; 1996 Mar; 39(3):353-6. PubMed ID: 8721783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats.
    Vettor R; Zarjevski N; Cusin I; Rohner-Jeanrenaud F; Jeanrenaud B
    Diabetologia; 1994 Dec; 37(12):1202-8. PubMed ID: 7895949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenalectomy prevents the obesity syndrome produced by chronic central neuropeptide Y infusion in normal rats.
    Sainsbury A; Cusin I; Rohner-Jeanrenaud F; Jeanrenaud B
    Diabetes; 1997 Feb; 46(2):209-14. PubMed ID: 9000696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of neuropeptide Y (NPY) Y5 receptor-mediated obesity in mice: chronic intracerebroventricular infusion of D-Trp(34)NPY.
    Mashiko S; Ishihara A; Iwaasa H; Sano H; Oda Z; Ito J; Yumoto M; Okawa M; Suzuki J; Fukuroda T; Jitsuoka M; Morin NR; MacNeil DJ; Van der Ploeg LH; Ihara M; Fukami T; Kanatani A
    Endocrinology; 2003 May; 144(5):1793-801. PubMed ID: 12697685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Intracerebroventricular Administration of Neuropeptide Y on Metabolic Gene Expression and Energy Metabolism in Male Rats.
    Su Y; Foppen E; Fliers E; Kalsbeek A
    Endocrinology; 2016 Aug; 157(8):3070-85. PubMed ID: 27267712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic central melanocortin-4 receptor antagonism and central neuropeptide-Y infusion in rats produce increased adiposity by divergent pathways.
    Baran K; Preston E; Wilks D; Cooney GJ; Kraegen EW; Sainsbury A
    Diabetes; 2002 Jan; 51(1):152-8. PubMed ID: 11756335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central neuropeptide Y infusion and melanocortin 4 receptor antagonism inhibit thyrotropic function by divergent pathways.
    Preston E; Cooney GJ; Wilks D; Baran K; Zhang L; Kraegen EW; Sainsbury A
    Neuropeptides; 2011 Dec; 45(6):407-15. PubMed ID: 21862125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism.
    Billington CJ; Briggs JE; Grace M; Levine AS
    Am J Physiol; 1991 Feb; 260(2 Pt 2):R321-7. PubMed ID: 1996719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of hypothalamic neuropeptide Y gene expression by insulin.
    Schwartz MW; Sipols AJ; Marks JL; Sanacora G; White JD; Scheurink A; Kahn SE; Baskin DG; Woods SC; Figlewicz DP
    Endocrinology; 1992 Jun; 130(6):3608-16. PubMed ID: 1597158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute intracerebroventricular administration of neuropeptide Y stimulates corticosterone output and feeding but not insulin output in normal rats.
    Sainsbury A; Rohner-Jeanrenaud F; Grouzmann E; Jeanrenaud B
    Neuroendocrinology; 1996 Apr; 63(4):318-26. PubMed ID: 8739887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective dependence of intracerebroventricular neuropeptide Y-elicited effects on central glucocorticoids.
    Zakrzewska KE; Sainsbury A; Cusin I; Rouru J; Jeanrenaud B; Rohner-Jeanrenaud F
    Endocrinology; 1999 Jul; 140(7):3183-7. PubMed ID: 10385413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic administration of neuropeptide Y into the lateral ventricle inhibits both the pituitary-testicular axis and growth hormone and insulin-like growth factor I secretion in intact adult male rats.
    Pierroz DD; Catzeflis C; Aebi AC; Rivier JE; Aubert ML
    Endocrinology; 1996 Jan; 137(1):3-12. PubMed ID: 8536627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic and orexigenic effects of intracerebroventricular neuropeptide Y are attenuated by food deprivation.
    Parikh R; Marks JL
    J Neuroendocrinol; 1997 Oct; 9(10):789-95. PubMed ID: 9355048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropeptide Y administered chronically into the lateral ventricle profoundly inhibits both the gonadotropic and the somatotropic axis in intact adult female rats.
    Catzeflis C; Pierroz DD; Rohner-Jeanrenaud F; Rivier JE; Sizonenko PC; Aubert ML
    Endocrinology; 1993 Jan; 132(1):224-34. PubMed ID: 8380374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central insulin administration reduces neuropeptide Y mRNA expression in the arcuate nucleus of food-deprived lean (Fa/Fa) but not obese (fa/fa) Zucker rats.
    Schwartz MW; Marks JL; Sipols AJ; Baskin DG; Woods SC; Kahn SE; Porte D
    Endocrinology; 1991 May; 128(5):2645-7. PubMed ID: 2019270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some acute effects of intracerebroventricular neuropeptide Y on insulin secretion and glucose metabolism in the rat.
    Marks JL; Waite K
    J Neuroendocrinol; 1996 Jul; 8(7):507-13. PubMed ID: 8843019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined deletion of Y1, Y2, and Y4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity.
    Lin EJ; Sainsbury A; Lee NJ; Boey D; Couzens M; Enriquez R; Slack K; Bland R; During MJ; Herzog H
    Endocrinology; 2006 Nov; 147(11):5094-101. PubMed ID: 16873543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability.
    Kanatani A; Kanno T; Ishihara A; Hata M; Sakuraba A; Tanaka T; Tsuchiya Y; Mase T; Fukuroda T; Fukami T; Ihara M
    Biochem Biophys Res Commun; 1999 Dec; 266(1):88-91. PubMed ID: 10581170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.